Responsiveness to P2Y12 receptor inhibitors

Current Opinion in Cardiology

Volumn 26, Issue SUPPL. 1, 2011, Pages

  Esposito, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

2 mutation; Clopidogrel; CY2C19 system; Drug resistance; Genetic test; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 2C19; ELINOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; RAPAMYCIN; TICAGRELOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; GENE MUTATION; GENOTYPE; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DRUG RESISTANCE; HUMANS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 82555172139     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/01.hco.0000409965.20588.c5     Document Type: Article

References (28)

1. Taubert D, Kastrati A, Harlfinger S. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92:311-316. (Pubitemid 39172312)
2. Taubert D, von Beckerath N, Grimberg G. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80:486-501. (Pubitemid 44767878)
3. Mega JL, Close SL, Wiviott SD. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312-1319.
4. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19-2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56:134-143.
5. Hochholzer W, Trenk D, Fromm MF. Impact of cytochrome P450 2C19 lossof-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55:2427-2434.
6. Shuldiner AR, O'Connell JR, Bliden KP. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302:849-857.
7. Pareé G, Mehta SR, Yusuf S. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363:1704-1714.
8. Taubert D, Bouman HJ, van Werkum JW. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:2249-2250.
9. Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17:110-116.
10. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32:1605-1613.
11. Camps J, Joven J, Mackness B, et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011; 17:1041-1042.
12. Aleil B, Jacquemin L, De Poli F. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008; 1:631-638.
13. Bouman HJ, Parlak E, van Werkum JW. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8:482-488.
14. Cuisset T, Cayla G, Silvain J. Clopidogrel resistance: what's new? Arch Cardiovasc Dis 2010; 103:349-353.
15. Paniccia R, Antonucci E, Maggini N. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104:287-292.
16. KozinskiM, Bielis L, Wisniewska-Szmyt J. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011. [Epub ahead of print]
17. Abualsaud AO, Eisenberg MJ. Perioperative Management of Patients With Drug-Eluting Stents. JACC Cardiovasc Interv. 2010; 3:131-142.
18. Wijns W, Kolh P, Danchin N, et al.Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31:2501-2555.
19. Price MJ, Berger PB, Teirstein PS. Standard vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305:1097-1105.
20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49:1505-1516. (Pubitemid 46517957)
21. Hochholzer W, Trenk D, Bestehorn HP. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48:1742-1750. (Pubitemid 44648629)
22. Sibbing D, Braun S, Morath T. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:849-856.
23. Price MJ, Endemann S, Gollapudi RR. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29:992-1000. (Pubitemid 351844676)
24. Combescue C, Fontana P, Mallouk N. Clinical implications of clopidogrel nonresponse in cardiovascular patients: a systematic review and metaanalysis. Thromb Haemost 2010; 8:923-933.
25. Bonello L, Camoin-Jau L, Arques S, Boyer C. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51:1404-1411. (Pubitemid 351447314)
26. Mehta SR, Tanguay JF, Eikelboom JW, et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:1233-1243.
27. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119:3215-3222; Epub 2009 Jun 15.
28. Bellemain-Appaix A, Brieger D, Beygui F. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol 2010; 56:1542-1551.